Personal Health: After a Hip Fracture, Reducing the Risk of a Recurrence

Following a fracture, patients should have a bone density test, evaluation of calcium and vitamin D levels and, in nearly all cases, medication to protect against further bone loss.
Source: NYT Health - Category: Consumer Health News Authors: Tags: Bone Fractures Hips Bones Falls Osteoporosis Source Type: news

Related Links:

ConclusionLPS and XLGB co-treatment in rats led to marked hepatotoxicity. This toxicity was associated with disrupted lipid metabolism, extensive liver necrosis and inflammatory infiltration, apoptosis, and expression of oxidative stress-related proteins. These results demonstrate a valuable model for the study of iDILI in the context of XLGB treatment, and further provide insights into the potential mechanisms by which XLGB may induce hepatotoxicity in humans.Graphical abstract
Source: Journal of Ethnopharmacology - Category: Drugs & Pharmacology Source Type: research
Authors: Liu Y, Li Y, Liu X, Wang CS Abstract Microarray data of osteoporosis (OP) were analyzed based on prediction of transcription factors (TFs) or their targets as well as influences of TFs or TF network to uncover key TFs in OP. The microarray data E-GEOD-35956 was downloaded from the GPL570 platform. Differentially expressed genes (DEGs) with logarithm of fold change (|logFC|)>2 and P-value
Source: Experimental and Therapeutic Medicine - Category: General Medicine Tags: Exp Ther Med Source Type: research
ConclusionsThese findings suggest that prenatal skeletal loading may exert long-lasting influences on skeletal size and strength but require replication.
Source: Osteoporosis International - Category: Orthopaedics Source Type: research
Conclusions World population is aging and the increase in life expectancy is often unhealthy. In particular, musculoskeletal aging, which leads to sarcopenia and osteoporosis, has several causes such as changes in body composition, inflammation, and hormonal imbalance. Sarcopenia, osteoporosis, and more frequently, sarcopenic obesity are commonly associated with aging and frequently closely linked each other, often leading to the development of a frailty syndrome. Frailty syndrome favors an increased risk of loss function in daily activities, for cardiovascular diseases, cancers, falls, and mortality. As the number of eld...
Source: Frontiers in Endocrinology - Category: Endocrinology Source Type: research
Effects of Aging and Caloric Restriction on Fiber Type Composition, Mitochondrial Morphology and Dynamics in Rat Oxidative and Glycolytic Muscles Julie Faitg1,2, Jean-Philippe Leduc-Gaudet2,3,4, Olivier Reynaud2,4, Guylaine Ferland5,6, Pierrette Gaudreau7,8 and Gilles Gouspillou2,9* 1Département de Biologie, Faculté des Sciences, UQAM, Montreal, QC, Canada 2Groupe de recherche en Activité Physique Adaptée, Montreal, QC, Canada 3Meakins-Christie Laboratories, Department of Medicine and Division of Experimental Medicine, McGill University, Montreal, QC, Canada 4Département des scie...
Source: Frontiers in Physiology - Category: Physiology Source Type: research
ConclusionsAlthough the risk of bone fracture was high in this case, treatment approaches differ between osteoporosis and hypophosphatasia. Because adult hypophosphatasia diagnosis is often difficult because of their varied symptoms, hypophosphatasia should be considered in the differential diagnosis of low serum alkaline phosphatase. Early diagnosis is important so that appropriate treatment can be initiated.
Source: Journal of Medical Case Reports - Category: General Medicine Source Type: research
A variety of drugs are effective for preventing osteoporotic fractures, but there are gaps in the evidence supporting their safety and effectiveness beyond three years, according to a National Institutes of Health Pathways to Prevention Workshop.Reuters Health Information
Source: Medscape Medical News Headlines - Category: Consumer Health News Tags: Internal Medicine News Source Type: news
Condition:   Postmenopausal Osteoporosis Interventions:   Drug: Prolia®;   Drug: CMAB807 Sponsor:   Shanghai Biomabs Pharmaceutical Co., Ltd. Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Conditions:   Parkinson Disease;   Osteoporosis Interventions:   Drug: Zoledronic Acid 5Mg/Bag 100Ml Inj;   Other: Placebo Sponsors:   California Pacific Medical Center Research Institute;   National Institute on Aging (NIA);   University of California, San Francisco;   Duke University;   University of Pittsburgh;   Parkinson's Foundation Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Condition:   Postmenopausal Osteoporosis Interventions:   Drug: Prolia®;   Drug: CMAB807 Sponsor:   Shanghai Biomabs Pharmaceutical Co., Ltd. Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Calcium | Health | Orthopaedics | Osteoporosis | Vitamin D | Vitamins